

**INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES**

OMB APPROVAL	
OMB Number:	3235-0104
Estimated average burden hours per response:	0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Clarus Lifesciences II, L.P.</u>  (Last) (First) (Middle) 101 MAIN STREET SUITE 1210  (Street) CAMBRIDGE MA 02142  (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) 10/11/2017	3. Issuer Name and Ticker or Trading Symbol <u>Restoration Robotics Inc [ HAIR ]</u>	
		4. Relationship of Reporting Person(s) to Issuer (Check all applicable)  Director <input checked="" type="checkbox"/> 10% Owner  Officer (give title below) Other (specify below)	5. If Amendment, Date of Original Filed (Month/Day/Year)  6. Individual or Joint/Group Filing (Check Applicable Line) Form filed by One Reporting Person <input checked="" type="checkbox"/> Form filed by More than One Reporting Person

**Table I - Non-Derivative Securities Beneficially Owned**

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
---------------------------------	---	--	---

**Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
Series C Preferred Stock	(1)	(2)	Common Stock	3,389,105	(1)	D <sup>(3)</sup>	

1. Name and Address of Reporting Person* <u>Clarus Lifesciences II, L.P.</u>  (Last) (First) (Middle) 101 MAIN STREET SUITE 1210  (Street) CAMBRIDGE MA 02142  (City) (State) (Zip)		
---	--	--

1. Name and Address of Reporting Person* <u>Clarus Ventures II GP, L.P.</u>  (Last) (First) (Middle) 101 MAIN STREET SUITE 1210  (Street) CAMBRIDGE MA 02142  (City) (State) (Zip)		
--	--	--

1. Name and Address of Reporting Person* <u>Clarus Ventures II, LLC</u>  (Last) (First) (Middle) 101 MAIN STREET SUITE 1210  (Street) CAMBRIDGE MA 02142  (City) (State) (Zip)		
--	--	--

(City)	(State)	(Zip)
1. Name and Address of Reporting Person*		
<a href="#">Simon Nicholas</a>		
(Last)	(First)	(Middle)
101 MAIN STREET, SUITE 1210		
(Street)		
CAMBRIDGE	MA	02142
(City) (State) (Zip)		
1. Name and Address of Reporting Person*		
<a href="#">LIPTAK ROBERT</a>		
(Last)	(First)	(Middle)
101 MAIN STREET, SUITE 1210		
(Street)		
CAMBRIDGE	MA	02142
(City) (State) (Zip)		
1. Name and Address of Reporting Person*		
<a href="#">GALAKATOS NICHOLAS</a>		
(Last)	(First)	(Middle)
101 MAIN STREET, SUITE 1210		
(Street)		
CAMBRIDGE	MA	02142
(City) (State) (Zip)		
1. Name and Address of Reporting Person*		
<a href="#">HENNER DENNIS</a>		
(Last)	(First)	(Middle)
101 MAIN STREET, SUITE 1210		
(Street)		
CAMBRIDGE	MA	02142
(City) (State) (Zip)		
1. Name and Address of Reporting Person*		
<a href="#">WHEELER KURT</a>		
(Last)	(First)	(Middle)
101 MAIN STREET, SUITE 1210		
(Street)		
CAMBRIDGE	MA	02142
(City) (State) (Zip)		

**Explanation of Responses:**

1. The shares of the Issuer's Preferred Stock automatically convert into shares of the Issuer's Common Stock, for no additional consideration, on a 1:1 basis immediately prior to the consummation of the Issuer's Initial Public Offering (the "IPO").
2. The expiration date is not relevant to the conversion of these securities.
3. The shares are directly held by Clarus Lifesciences II, L.P. ("Clarus"). Clarus Ventures II GP, L.P. (the "GPLP"), as the sole general partner of Clarus, may be deemed to beneficially own certain of the shares held by Clarus. Clarus Ventures II, LLC (the "GPLLC"), as the sole general partner of the GPLP, may be deemed to beneficially own certain of the shares held by Clarus. Each of the GPLP and the GPLLC disclaim beneficial ownership of all shares held by Clarus in which it does not have an actual pecuniary interest.

[/s/ Robert Liptak, Attorney-in-Fact for Clarus Lifesciences II, L.P.](#) 10/11/2017

[/s/ Robert Liptak, Attorney-in-Fact Clarus Ventures II GP, L.P.](#) 10/11/2017

[/s/ Robert Liptak, Attorney-in-Fact](#) 10/11/2017

[Fact for Clarus Ventures II, LLC](#)

[/s/ Robert Liptak, Attorney-in-Fact for Nicholas Simon](#) [10/11/2017](#)

[/s/ Robert Liptak, Attorney-in-Fact for Nicholas Galakatos](#) [10/11/2017](#)

[/s/ Robert Liptak, Attorney-in-Fact for Dennis Henner](#) [10/11/2017](#)

[/s/ Robert Liptak, Attorney-in-Fact for Kurt Wheeler](#) [10/11/2017](#)

[/s/ Robert Liptak](#) [10/11/2017](#)

\*\* Signature of Reporting Person      Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**